The Journal for Nurse Practitioners
Volume 4, Issue 9 , Pages 681-687 , October 2008

Latent Autoimmune Diabetes in Adults

  • Jane Kapustin

      Affiliations

    • Jane Kapustin, PhD, CRNP, is the assistant dean for master's studies and an associate professor at the University of Maryland School of Nursing and an NP at Joslin Diabetes Center at University of Maryland Medical Center.

References 

  1. Sanjeevi CB . Genes influencing innate and acquired immunity in type 1 diabetes and latent autoimmune diabetes in adults . Ann N Y Acad Sci . 2006;1079:67–80
  2. Zinman B , Kahn SE , Haffner SM , O'Neill C , Heise MA , et al.   Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe . Diabetes . 2005;53(12):3193–3200
  3. Palmer JP , Hirsch IB . What's in a name? Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes . Diabetes Care . 2003;26:536–538
  4. Landin-Olsson M . Latent autoimmune diabetes in adults . Ann N Y Acad Sci . 2002;958(1):112–116
  5. Beyan H , Ola T , Leslie G . Progression of autoimmune diabetes: slowly progressive insulin-dependent diabetes mellitus or latent autoimmune diabetes of adult . Ann N Y Acad Sci . 2006;1079:81–89
  6. Housszufalusi N , Vatay A , Rajczy K , Prohaszka Z , Horvath L , et al.   Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression . Diabetes Care . 2003;26:452–457
  7. Leslie DG , Williams R , Pozzilli P . Clinical review: type 1 diabetes and latent autoimmune diabetes in adults; one end of the rainbow . J Clin Endocrinol Metab . 2006;91:1654–1659
  8. Stenstrom G , Gottsater A , Bakhtadze E , Berger B , Sundkvist G . Latent autoimmune diabetes in adults: definition, prevalence, beta cell function and treatment . Diabetes . 2005;54(Suppl 2):S68–S72
  9. Beyan H , Ola T , David R , Leslie G . Progression of autoimmune diabetes. Slowly progressive insulin-dependent diabetes mellitus or latent autoimmune diabetes of adult . Ann N Y Acad Sci . 2006;1079:81–89
  10. Zinman B , Kahn SE , Haffner SM , O'Neill MC , Heise MA , et al.   Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe . Diabetes . 2004;53(12):3193–3200
  11. Turner R , Stratton I , Horton V , et al.   UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group . Lancet . 1997;350(9087):1288–1293
  12. Nabhan F , Emanuele MA , Emanuele N . Latent autoimmune diabetes of adulthood: unique features that distinguish it from types 1 and 2 . Postgrad Med . 2005;117(3):7–12
  13. Rosario PWS , Reis JS , Amim R , Fagundes TA , Calsolari MR , et al.   Comparison of clinical and laboratory characteristics between adult-onset type 1 diabetes and latent autoimmune diabetes in adults . Diabetes Care . 2005;28(7):1803–1804
  14. Fourlanos S , Perry C , Stein MS , Stankovich J , Harrison LC , et al.   A clinical screening tool identifies autoimmune diabetes in adults . Diabetes Care . 2006;29(5):970–975
  15. Johnson JD . Pancreatic beta-cell apoptosis in maturity onset diabetes of the young . Can J Diabetes . 2007;31(1):67–74
  16. Torn C , Landin-Olsson M , Ostman J , et al.   Glutamic acid decarboxylase autoantibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as type 1 diabetes on clinical grounds . Diabetes Metabol Res Rev . 2000;16(6):442–447
  17. Brophy S , Brunt H , Davies H , Mannan S , Williams R . Interventions for latent autoimmune diabetes (LADA) in adults . Cochrane Database Syst Rev . 2006; 3. Art. No.: CD006165
  18. Cabrera-Rode E , Perich P , Diaz-Horta O , Tiberti C , Molina G , et al.   Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclaminde treatment . Autoimmunity . 2002;35(7):469–474
  19. Kobayashi T , Nakanishi K , Murase T , Kasaka K . Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta cell failure in islet cell antibody positive patients with clinical features of NIDDM . Diabetes . 1996;45:622–626
  20. Maruyama T , Shimada A , Kanatsuka A , Takei I , Yokoyama J , et al.   Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo Study) . Ann N Y Acad Sci . 2003;1005:362–369
  21. Takino H , Yamasaki H , Sera Y , Abe T , Ozaki M , et al.   The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed with type 2 in Japan . Diabetes Metab Rev . 1998;14:329–335
  22. Zhou Z , Li X , Huang G , Peng J , Yang L , et al.   Rosiglitazone combined with insulin preserves islet beta cell function in adult onset latent autoimmune diabetes (LADA) . Diabetes Metab Res Rev . 2005;21:203–208
  23. Beales PE , Giorgini A , Annovazzi A , et al.   Metformin does not alter diabetes incidence in the NOD mouse . Hormone Metab Res . 1997;29(6):261–263
  24. Agardh CD , Cilio C , Lethagen A , Lynch K , Leslie D , et al.   Clinical evidence for the safety of GAD 65 immunomodulation in adult-onset autoimmune diabetes . J Diabetes Complications . 2005;19:238–246
  25. American Diabetes Association  . Clinical practice recommendations . Diabetes Care . 2008;31(1):S1–S108

 In compliance with national ethical guidelines, the author reports no relationships with business or industry that would pose a conflict of interest.

PII: S1555-4155(08)00409-1

doi: 10.1016/j.nurpra.2008.06.004

The Journal for Nurse Practitioners
Volume 4, Issue 9 , Pages 681-687 , October 2008

Article Tools

* Image Usage & Resolution